214390.Ks

The company's capital structure is characterized by a debt-to-equity ratio of 0.87, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.08 and a negative net cash position after subtracting total debt. The price-to-book ratio is 1.0, and the price-to-tangible-book ratio is also 1.0, suggesting that the market value aligns closely with the book value of tangible assets.

Profitability metrics show a return on equity of 0.0013 and a return on assets of 0.0006, both of which are below typical thresholds for strong performance in the pharmaceutical industry. The company's operating income is 3,518,577,340 KRW, and its net income is 182,293,090 KRW, indicating a relatively low net margin. The gross profit of 102,304,221,420 KRW suggests that the company is able to maintain a reasonable gross margin, but the low net income indicates significant operating expenses or other costs.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to higher risks associated with market fluctuations in its primary operating region. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets or product lines.

The company's growth trajectory is not clearly defined in the available data, as there are no specific numeric deltas provided for the current or next fiscal year. However, the company's free cash flow is negative at -29,423,297,640 KRW, and its capital expenditure is -41,614,182,730 KRW, indicating a significant outflow of cash for investment in capital assets. This suggests that the company is investing heavily in its operations, which could be a sign of growth initiatives or expansion.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity challenges. The dilution risk is assessed as low, suggesting that the company is not expected to issue additional shares in the near term. The absence of dilution sources in the provided data means that the low dilution risk is based on the current capital structure and not on any specific disclosures about potential future dilution.

Recent events and filings are not detailed in the provided data, so there is no information available about recent corporate actions, earnings reports, or other significant events that may have impacted the company's financial position or strategic direction. The lack of recent events data limits the ability to assess the company's current performance and future outlook.